Intersect ENT Stock Forecast, Price & News

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

Is Intersect ENT a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT or view top-rated stocks.

What stocks does MarketBeat like better than Intersect ENT?

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Intersect ENT.

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its quarterly earnings data on Friday, August, 6th. The medical equipment provider reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.07. The medical equipment provider earned $27.30 million during the quarter, compared to analyst estimates of $27.77 million. Intersect ENT had a negative trailing twelve-month return on equity of 102.23% and a negative net margin of 66.55%. Intersect ENT's revenue was up 178.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.65) earnings per share.
View Intersect ENT's earnings history.

How has Intersect ENT's stock price been impacted by Coronavirus?

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, XENT stock has increased by 25.3% and is now trading at $26.94.
View which stocks have been most impacted by COVID-19.

What guidance has Intersect ENT issued on next quarter's earnings?

Intersect ENT updated its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $117 million-$121 million, compared to the consensus revenue estimate of $119.79 million.

What price target have analysts set for XENT?

5 Wall Street analysts have issued 12-month price targets for Intersect ENT's shares. Their forecasts range from $23.00 to $32.00. On average, they expect Intersect ENT's share price to reach $27.96 in the next year. This suggests a possible upside of 3.8% from the stock's current price.
View analysts' price targets for Intersect ENT or view top-rated stocks among Wall Street analysts.

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the following people:

• Thomas A. West, President, Chief Executive Officer & Director
• Randy Meier, Chief Financial Officer & Executive Vice President
• Patrick A. Broderick, Secretary, Executive VP & General Counsel
• Mark L. Alley, Vice President-Sales
• Reyna M. Fernandez, Chief Human Resource Officer

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT CEO Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Intersect ENT's key competitors?

Some companies that are related to Intersect ENT include The Beauty Health (SKIN), AtriCure (ATRC), Axonics (AXNX), NuVasive (NUVA), Glaukos (GKOS), Silk Road Medical (SILK), iRhythm Technologies (IRTC), Pulmonx (LUNG), Inovio Pharmaceuticals (INO), Cardiovascular Systems (CSII), Atrion (ATRI), OrthoPediatrics (KIDS), Sight Sciences (SGHT), LeMaitre Vascular (LMAT) and Alphatec (ATEC).
View all of XENT's competitors.

What other stocks do shareholders of Intersect ENT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG), Air Transport Services Group (ATSG), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and AbbVie (ABBV).

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by many different retail and institutional investors. Top institutional investors include Havens Advisors LLC (0.27%), Strs Ohio (0.10%) and Sphinx Trading LP (0.02%). Company insiders that own Intersect ENT stock include Richard A Meier, Robert H Binney, Jr and Thomas A West.
View institutional ownership trends for Intersect ENT.

Which institutional investors are buying Intersect ENT stock?

XENT stock was bought by a variety of institutional investors in the last quarter, including Havens Advisors LLC, Strs Ohio, and Sphinx Trading LP. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT or or view top insider-buying stocks.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $26.94.

How much money does Intersect ENT make?

Intersect ENT has a market capitalization of $900.33 million and generates $80.55 million in revenue each year. The medical equipment provider earns $-72.32 million in net income (profit) each year or ($2.05) on an earnings per share basis.

How many employees does Intersect ENT have?

Intersect ENT employs 406 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is www.intersectent.com.

Where are Intersect ENT's headquarters?

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at (650) 641-2100 or via email at [email protected].